Silexion Therapeutics Corp
SLXNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002022416
No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $98.7K in total; no superinvestor holds it.
Other share classesSLXN
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Silexion Therapeutics Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Silexion Therapeutics Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hadar Ilan | Chairman and CEO | 16,547 | Jun 8, 2026 | 2 |
| Shirvan Mitchell | CSO and CDO | 8,789 | Jun 8, 2026 | 3 |
| Horenshtein Hadar Mirit | CFO and Secretary | 12,515 | Jun 8, 2026 | 2 |
| Noy Shlomo | Director | 25,399Indirect | Feb 25, 2026 | 2 |
| Alon Ruth | Director | 10,228 | Feb 23, 2026 | 2 |
| Lushi Avner | Director | 25,399Indirect | Feb 23, 2026 | 2 |
| Abramov Dror Yosef | Director | 10,180 | Feb 23, 2026 | 2 |
| Peled Amnon | Director | 8,237 | Feb 23, 2026 | 2 |
| Levin Ilan | Director, 10% Owner | 456,970Indirect | Jan 27, 2026 | 1 |
| Moringa Sponsor, LP | 10% Owner | 456,970Indirect | Jan 27, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Shirvan MitchellCSO and CDO | SSale | −22.8K | $1.36 | −$31.0K | −45.0%27.9K after |